Home > Inhibitors & Agonists > Cell Cycle/DNA Damage > Cyclin-dependent Kinase (CDK)

Cyclin-dependent Kinase (CDK)

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC8596 Cdk4/6 Inhibitor IV Cdk4/6 Inhibitor IV is a cell-permeable triaminopyrimidine compound acting as a reversible and ATP-competitive inhibitor of Cdk4/6 (IC50 = 1.5 µM and 5.6 µM for Cdk4/D1 and Cdk6/D1, respectively)
DC9478 CDK9-IN-1 CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection.
DC9390 CDK-IN-2 Featured CDK-IN-2 is a potent and sepecific CDK inhibitor.
DC11164 Compound 919278 Compound 919278 is a specific inhibitor of lymphotoxin β receptor (LTβR, IC50=0.169 uM), and TNF receptor superfamily member 12A (FN14)-dependent nuclear translocation of p52 (IC50=0.167 uM) via inhibiting CDK12/CCNK, does not inhibit the TNF-α-mediated nuclear translocation of p65 (RelA).
DC9306 CVT-313(NG-26) Featured CVT-313(NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
DC10775 Fadraciclib (CYC065) Featured CYC065 is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9) with potential antineoplastic and chemoprotective activities.
DC7114 Dinaciclib (SCH727965) Featured Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.
DC11864 Fascaplysin (chloride)|CDK4 inhibitor Featured Fascaplysin is a potent, selective ATP-competitive CDK4 inhibitor (IC50 = 350 nM).
DC2014 Flavopiridol Featured Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM, and CDK7 with IC50 of 300 nM.
DC8780 Flavopiridol Hydrochloride Featured Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA.
DC10501 G1T28(Trilaciclib) Featured G1T28(Trilaciclib) is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy.
DC11303 CT7001 hydrochloride Featured ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.
DC7178 JNJ-7706621 Featured JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6; also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
DC5093 NSC-664704(Kenpaullone) Featured Kenpaullone is an ATP-competitive inhibitor of several cyclin-dependent kinases (CDKs) as well as glycogen synthase kinase 3β (GSK3β).
DC9394 LDC000067 Featured LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7.
DC10143 LDC-4297 Featured LDC4297 is a novel CDK7 inhibitor.
DC9773 LEE011 hydrochloride Featured LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
DC7453 Ribociclib (LEE011) Featured LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
DC9774 LEE011 succinate Featured LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
DC8643 LY2835219 free base (Abemaciclib) Featured LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
DC5062 LY2835219(Abemaciclib) Featured LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
DC9766 LY3177833 Featured LY3177833 is a novel CDC7 inhibitor,CDC7/DBF4 IC50 = 3.3 nM, pMCM2 (S53) IC50 = 290 nM and IVTI TEC70 = 1.6 mcM.
DC9741 Mad2 inhibitor-1 (M2I-1) Featured Mad2 Inhibitor-1 (M2I-1) is a small molecule protein-protein interaction inhibitor targeting the mitotic spindle assembly checkpoint.
DC10627 MSC2530818 Featured MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.
DC9988 NSC23005 sodium Featured NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
DC8214 NU6027 Featured NU 6027 inhibits both CDK1 and CDK2 with IC50 values of 2.9 and 2.2 µM, respectively.
DC10734 NU2058 Featured NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1.
DC8716 NU6300 NU6300 is a non-covalent ATP-competitive CDK2 inhibitor (IC50 = 0.16 mM).
DC9392 NVP-LCQ195 Featured NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
DC9253 ON123300 Featured ON123300 is a novel multiple kinase inhibitor.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia